Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for sofosbuvir and velpatasvir

  1. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

    Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    21 February 2018
    View recommendations

    Sections for TA507

  2. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

    Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA430

  3. Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

    Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

    Technology appraisal guidance
    Published
    24 January 2018
    View recommendations

    Sections for TA499